Cutia Therapeutics (HKSE:02487) Accounts Payable & Accrued Expense : HK$37.1 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Accounts Payable & Accrued Expense?

Cutia Therapeutics's quarterly accounts payable & accrued expense increased from Jun. 2023 (HK$33.5 Mil) to Dec. 2023 (HK$85.3 Mil) but then declined from Dec. 2023 (HK$85.3 Mil) to Jun. 2024 (HK$37.1 Mil).

Cutia Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 (HK$10.0 Mil) to Dec. 2022 (HK$49.1 Mil) and increased from Dec. 2022 (HK$49.1 Mil) to Dec. 2023 (HK$85.3 Mil).

Cutia Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Cutia Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Accounts Payable & Accrued Expense Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

10.05

49.07

85.35

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			-	49.07	33.48	85.35	37.12

Cutia Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Cutia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.

Executives

Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hsg Holding Limited	2201 Interest of corporation controlled by you
Ma Yun	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Aurora Cutis Limited	2301 Trustee

Cutia Therapeutics Headlines

No Headlines